This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Pascal Geldsetzer believes in open access, in disseminating science as quickly as it happens. Even so, last summer, as he uploaded the surprising results of his latest study to the MedRxiv preprint server, the Stanford University epidemiologist was feeling something other than the usual excitement. “I was scared to put this up because it’s such a different approach from what’s generally done in epidemiology and medicine,” he said.
Sanofi invests €300m in Orano Med's lead-based radioligandsSanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear fuel company Orano.The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 million upfront payment – to develop a radioligand therapy (RLT) for rare neuroendocrine tumours (NETs) c
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $63 billion in 2023, a 23.4% increase from the previous year, according to the Health Resources & Services Administration, which oversees the program. The data mark a steady rise in sales under the 340B Drug Discount Program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — off all outpatient drugs to hospit
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
As a child in Jacksonville, Fla., Alex Chern built string instruments out of office supplies and tuned them, stretching rubber bands taut to change their pitch. Starting at age 7, he took violin lessons and continued playing all the way through college at Yale University. He loved playing Beethoven, expressive pieces written in F major like “Romance No. 2” or the “Spring Sonata,” and technically challenging pieces like Bach’s “Sonatas and Partitas,ȁ
Women in deprived areas are accessing hormone replacement therapy (HRT) on the NHS at nearly half the rate of women in more affluent areas, the latest data shows. According to analysis by The Pharmacist, just 10% of women aged 45-59 living in the 20% most deprived areas in England were given HRT on the NHS in […] The post Women in more deprived areas half as likely to access HRT, data shows appeared first on The Pharmacist.
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who were wise enough to attend, hope you enjoyed this year’s STAT Summit. Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more.
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning! For those who were wise enough to attend, hope you enjoyed this year’s STAT Summit. Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more.
Nearly 60,000 hormone replacement therapy (HRT) items were supplied under a serious shortage protocol (SSP) in England last year, new data has revealed. And more than 13 million HRT items were supplied overall in England last year, according to the latest figures from the NHS Business Services Authority (NHSBSA). HRT shortages increase sixfold in a […] The post Nearly 60,000 HRT items supplied under SSPs last year appeared first on The Pharmacist.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. I’m recovering from the STAT Summit — in particular, recovering from this stunning view of Boston from the venue. On Wednesday evening, we had an amazing view of the almost-supermoon rising as dusk settled in during the last panel of the day.
CVS Health has replaced Karen Lynch with David Joyner as CEO, it said Friday, part of an attempt to turn the struggling company around. Joyner was previously the president of CVS Caremark, the company’s pharmacy benefit manager, and formerly worked at Aetna, the insurer now owned by CVS. The company said Lynch had stepped down “in agreement” with the company’s board.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
WASHINGTON — Californians are about to vote on an aggressive policy proposals to reform a drug discount program that is a key source of revenue for hospitals and health clinics. The group behind it? Apartment builders. As a general rule, programs named after the sub-section of the law in which they were created are not well-known. The 340B Drug Discount Program is no exception.
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You can also read Eli Lilly chief scientist Daniel M. Skovronsky on fallacies surrounding patents, drug discovery, and affordability, Sandoz CEO Richard Saynor on what the 2024 conversation is missin
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their insights on their differing challenges in a hot space for obesity drugs, an industry that doesn’t favor midsize companies, and a disappointing market for Alzheimer’s treatments — so far.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Scientists say using the drugs to get people back into work could carry logistical and ethical problems Weight loss jabs are not a “quick fix” and the health secretary’s plan to use them to help people get back to work could backfire, experts have warned. Wes Streeting announced a real-world trial of the medication’s impact on worklessness this week, saying that “widening waistbands” were placing a burden on the NHS.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo® (faricimab) for the treatment of diabetic macular edema (DME) in people from racial and ethnic groups that are often underrepresented in clinical trials.(4) The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data and Leqembi hit a roadblock in Australia.
With great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
A new immunotherapy treatment regimen (nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD)) provided a significant survival rate in advanced Hodgkin lymphoma patients, Phase III trial data shows. This new treatment could decrease long-term side effects including second cancers later in life and heart and lung conditions, according to the researchers.
The additions include Dextrose 70% intravenous (IV) solution, Lactated Ringers IV Solution, and Peritoneal Dialysis Solution, which were affected by Hurricane Helene.
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval in that indication.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
363 
Let's personalize your content